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Abstract
Background: A substantial proportion of HIV-infected adults starting antiretroviral therapy (ART) in sub-Saharan
Africa are malnourished. We aimed to increase understanding of the factors affecting their high mortality,
particularly in the high-risk period before ART initiation.
Methods: We analysed potential risk factors for mortality of Zambian and Tanzanian participants enrolled in the
NUSTART clinical trial. Malnourished adults (n = 1815; body mass index [BMI] <18.5 kg/m2) were recruited at referral
to ART and randomised to receive different nutritional supplements. Demographics, measures of body composition,
blood electrolytes and clinical conditions were investigated as potential risk factors using Poisson regression
models.
Results: The mortality rate was higher in the period from referral to starting ART (121 deaths/100 person-years;
95 % CI 103, 142) than during the first 12 weeks of ART (66; 95 % CI 57, 76) and was not affected by trial study arm.
In adjusted analyses, lower CD4 count, BMI and mid-arm circumference and raised C-reactive protein were
associated with an increased risk of mortality throughout the study. Male sex and lower hand-grip strength carried
an increased risk in the pre-ART period. Participants on tuberculosis treatment at referral had a lower mortality rate
(adjusted Rate Ratio 0.44; 95 % CI 0.31, 0.63).
Conclusion: Among malnourished ART-eligible adults, pre-ART mortality was twice that in the early post-ART
period, suggesting many early ART deaths represent advanced HIV disease rather than treatment-related events.
Therefore, more efforts are needed to promote earlier diagnosis and immediate initiation of ART, as recently
recommended by WHO for all persons with HIV worldwide. The positive effect of tuberculosis treatment suggests
undiagnosed tuberculosis is a contributor to mortality in this population.
Trial registration: Pan African Clinical Trials Registry, PACTR201106000300631; registered on 1st June 2011.
Keywords: Mortality risk factors, Malnutrition, ART, Africa
Background
The last decade has seen great advances in expanding
access to antiretroviral therapy (ART) for HIV-infected
Africans. However, high mortality immediately before
and in the first few months after starting ART remains a
major concern [1, 2]. Consistent risk factors for early
mortality include delayed ART initiation, indicated by
very low CD4 count or advanced WHO disease stage,
the presence of opportunistic infections such as tubercu-
losis (TB), and low body mass index (BMI) [1–3]. Male
sex, low haemoglobin, low serum phosphate and older
or younger age are additional risk factors for mortality
in some cohorts [4–9].
In our recent Nutritional Support for African Adults
Starting Antiretroviral Therapy (NUSTART) trial we
addressed malnutrition as a risk factor for mortality by
randomizing underweight African adults initiating ART
to a lipid-based nutritional supplement (LNS) containing
* Correspondence: andrea.rehman@lshtm.ac.uk
1Faculty of Epidemiology and Population Health, London School of Hygiene
& Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Woodd et al. BMC Infectious Diseases  (2016) 16:562 
DOI 10.1186/s12879-016-1894-3
multiple vitamins and minerals compared to LNS alone.
While we observed no difference in mortality between
treatment arms, the trial design provided a unique
opportunity for detailed clinical assessments of mal-
nourished, HIV-infected persons both prior to ART-
initiation and during the early months of treatment [10,
11]. We noted that the mortality rate between referral
for ART and 12 weeks after starting ART was consider-
ably higher, 83/100-person-years (95 % confidence
interval (CI) 75, 92), than in most other reports of early
mortality in patients starting ART in low-income
settings [1–3, 6, 12].
Many studies have reported mortality risk factors
among patients starting ART but, as far as we know,
none has included the high-risk period between referral
for ART and actually starting ART in a large cohort of
malnourished patients. Given the very high mortality
observed, we felt it important to analyse further the exten-
sive NUSTART database, including clinical conditions,
blood electrolytes and body composition, to determine
risk factors that could be used to improve clinical under-
standing and management of this vulnerable population.
Methods
Design and intervention
The NUSTART trial was a randomised, controlled phase
III trial with the primary outcome of mortality from re-
cruitment at referral to ART until 12 weeks after starting
ART and registered as PACTR201106000300631; details
have been described previously [10]. Briefly, the study
was conducted between August 2011 and December
2013 at two sites: the National Institute for Medical
Research (NIMR), Mwanza, Tanzania and the University
Teaching Hospital (UTH), Lusaka, Zambia.
The intervention was designed to mimic protocols for
nutritional management of severely malnourished chil-
dren [13] and was a lipid-based nutritional supplement,
made for the trial by Nutriset, Malaunay, France, either
with high levels of vitamins and minerals (LNS-VM) or
without (LNS). From recruitment at referral for ART to
2 weeks after starting ART, the LNS-VM or LNS was
given with minimal calories, i.e. 30 g/day, ~150 kcal/day.
From 2 to 6 weeks after initiating ART the LNS-VM or
LNS were given in 250 g/day, comprising ~1400 kcal/
day. Patients were followed to 12 weeks of ART.
Participant recruitment and follow-up
Adults attending free HIV testing services at both sites,
eligible for ART and fulfilling the study inclusion criteria
were deemed eligible for the trial. Inclusion criteria
were: at least 18 years old, ART-naive (except for previ-
ous short-term regimens to prevent maternal-to-child
HIV transmission), BMI < 18.5 kg/m2, requiring ART as
determined by CD4 count <350 cells/μl or stage 3 or 4
disease, willing to undertake intensive follow-up in the
study clinic and providing written (or thumbprint) in-
formed consent. Exclusion criteria were participation in
a potentially conflicting research protocol, or pregnancy
by self-report.
Medical care, including ART, was provided primarily
by local health services though study staff treated
minor illnesses and referred as necessary during pa-
tients’ study visits. National treatment guidelines for
ART regimen differed in the two countries: 74 % Zambians
were prescribed efavirenz, tenofovir, and emtricitabine,
whereas in Tanzania a wider range of regimens was used
(all comprising two nucleoside/nucleotide reverse tran-
scriptase inhibitors and a non-nucleoside reverse transcript-
ase inhibitor).
Patients were seen weekly from recruitment until they
initiated ART and then at 2, 4, 6, 8, and 12 weeks after
starting ART. Patients who were ill were invited to come
for unscheduled visits at any time. Patients who missed
scheduled visits were actively followed up through
phone-calls to patients and relatives, contact with their
ART clinic and additionally in Mwanza by visiting
patients at home. We therefore ascertained the primary
outcome of mortality before 12 weeks ART in 91 % of
the 1815 participants.
Data collection
Anthropometry, body composition, grip strength, and
haemoglobin
Patient weight and mid-upper arm circumference were
measured at all scheduled visits, and height at recruit-
ment. Measurements were taken in triplicate and the
median used in analyses. Staff were trained according to
standard protocols [14]. Technical errors of measure-
ment were within acceptable limits [15]. Body fat and
lean proportions were measured by bioelectrical imped-
ance (Tanita BC-418, Tokyo, Japan) and calibrated
against air displacement plethysmography results from a
sample of Lusaka patients [16]. Values were divided by
patient’s height squared to create an index. Grip strength
was measured using a digital handgrip dynamometer
(Takei TKK 5401, Chasmor, UK); two measurements were
taken from each hand and the machine takes the average
of the two maximum readings. Haemoglobin was mea-
sured in the clinic by Hemocue (Angelholm, Sweden).
Laboratory analyses
CD4 count was measured by local central clinical services.
Serum C-reactive protein (CRP) was measured by ELISA
(Assaypro, St Charles, MO, USA) in the site laboratories.
At both sites values for external quality control (QC) sera
(Assaypro) were within expected ranges but both the sites
had high inter-assay coefficients of variation (CV): 32 % in
Lusaka and 37 % in Mwanza. In Lusaka, serum phosphate
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was measured on a Pointe 180 analyser (Pointe Scientific,
Ann Arbor, MI, USA). Sample results were only accepted
from runs for which the external QC was within the
expected range. Inter-assay CV was 7 % for this external
QC. In Mwanza, serum phosphate was measured by
Roche COBAS Integra 400 analyser in an external labora-
tory (Bugando Medical Centre).
Appetite
Appetite was measured by a 4-question questionnaire,
combined to produce an appetite score using polycho-
ric correlation [17]. Lower scores represent lower appe-
tite. Preliminary analysis [18] indicated that the test
results were clustered in Lusaka and the score corre-
lated best with subsequent weight change in Tanzanian
patients. Therefore effect of appetite was only analysed
for Tanzanian patients.
Clinical signs and treatment
At each visit, patients were asked if they were taking
medications, including anti-TB drugs and cotrimoxazole.
All patients were examined at recruitment and assessed
for signs of oedema. When a patient died in hospital the
diagnosis recorded in the hospital records was taken as
the cause of death. Many patients died at home and the
cause of death was considered to be unknown.
Sample size
The planned sample size of 2300 participants was based
on the primary outcome of mortality. Recruitment was
stopped early because of a higher than expected mortal-
ity rate as previously described [10]. The final sample
size of 1815 was sufficient to detect, at 90 % power, a
mortality difference of 30 % between trial arms.
Data management and statistics
Data were double entered, checked and analyses were
conducted in STATA version 13.1. Risk factors at baseline
which were analysed for their associations with mortality
during the study were sex, age, socioeconomic status
(SES), CD4 count, BMI, haemoglobin, mid-upper arm
circumference (MUAC), fat-free mass index, fat-mass
index, oedema, TB treatment, cotrimoxazole treatment,
serum phosphate and CRP, grip strength, and appetite
score (for Tanzanians only). Principal components analysis
(PCA), used to describe the SES of the population, [19]
was conducted separately for each country since there
were notable differences between sites; variables offered
into the PCA were housing characteristics, sanitation,
water source, and ownership of electrical goods, animals
and modes of transport.
BMI, haemoglobin, fat-free mass index, fat mass
index and grip strength were used as continuous vari-
ables in regression analysis, after testing for linearity
using fractional polynomials. Age, CD4 count and CRP did
not have linear relationships and were categorised using
standard cut-offs for CD4 and in 4 groups for age (18–29,
30–39, 40–49, ≥50) and CRP (<10 mg/l, 10–49 mg/l, 50–
159 mg/l, ≥160 mg/l including the maximum cut-off for
most plates of 160 mg/l). Appetite score was divided into
tertiles. Serum phosphate was analysed as restricted cubic
splines with 4 knots to reflect the increased mortality
at high and low values. Low values were defined by
US National Institutes of Health Division of AIDS cri-
teria [20] and high values were considered any above
the normal range [21]. Continuous variables were also
categorised according to standard cut-offs or tertiles
for presentation of mortality rates.
Poisson regression was used to estimate hazard ratios.
Follow-up time was censored at 10 weeks if patients had
not yet started ART (n = 115) and these patients were ex-
cluded from all post-ART analysis to avoid the distorting
effect of a prolonged time from risk-factor measurement
to post-ART period. Factors associated with mortality in
univariable analysis were investigated in multivariable
models controlling for age, sex, CD4 count, BMI, TB
treatment, oedema, grip strength, treatment arm, study
site and follow-up time. BMI was omitted from the model
when analysing fat-free mass index and MUAC due to
collinearity and when analysing appetite as it could be
considered a mediator. Statistical significance was assessed
using Wald tests. After analysis of the total follow-up
time, the study was split into pre- and post-ART pe-
riods and baseline factors assessed for association with
mortality in each period. Thirty-one patients were
excluded due to missing information on ART start date,
including 19 patients who died. Interactions between
each risk factor and study period were tested in univari-
able analysis. Length of time spent pre-ART was
controlled for in post-ART analyses.
Results
Table 1 describes the population at recruitment. Charac-
teristics were similar at baseline between treatment arms
[10]. Half the cohort was male. At baseline a quarter of
participants had CD4 count < 50 cells/μl and mean BMI
was 16.7 kg/m2. Two-thirds of participants had moder-
ate or severe anaemia, 11 % had low serum phosphate
and 17 % reported taking TB treatment at their recruit-
ment visit (Table 1).
Participants spent a median of 14.3 weeks in the study
(IQR 10.4 to 15.7) and a median of 3 weeks (IQR 2.1 to
4.7) in the pre-ART period. The mortality rate from re-
cruitment until 12 weeks after starting ART was 83.1
deaths/100 person-years (95 % CI 75.0 to 92.1). In the pre-
ART period it was particularly high at 120.8 (95 % CI
103.0 to 141.7) and the rate increased as participants spent
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longer before starting ART, whereas it dropped to 66.1
(95 % CI 57.4 to 76.1) after ART initiation (Table 2).
Higher mortality rates were observed in participants
who were male, Tanzanian, or at recruitment had very
low CD4, BMI, haemoglobin, grip strength or appetite
scores, had very high CRP, had severely low or high
phosphate or oedema (Table 2). Grip strength and
MUAC showed strong independent associations with
mortality; rate of death decreased 6 % for every 1 kg
increase in grip strength and 13 % for every 1 cm gain in
MUAC. Patients receiving TB treatment at baseline had
less than half the mortality rate of those not on treat-
ment, after adjusting for other factors including CD4
count. Age, SES and treatment with co-trimoxazole at
recruitment had no association with mortality. Appetite
score, phosphate and fat-mass index showed crude asso-
ciations but these did not persist after adjusting for
other factors (Table 3).
In unadjusted analysis there is good evidence that the
association between CRP and mortality changes with
study period (p = 0.01) and in adjusted analysis the effect
of CRP on mortality appears larger after starting ART
than before (Table 4). There is at least weak evidence of
interactions between study period and each of study site,
sex and grip strength. In each case there is a strong
association with mortality in the pre-ART period with
Tanzanians, men and those with low grip strength hav-
ing an increased mortality rate. However, these associ-
ation do not appear to persist after starting ART. BMI,
fat-free mass index and MUAC measured at recruitment
have similar hazard ratios before and after starting ART
and no evidence of interaction with study period.
Baseline TB treatment was protective against mortality
in both time periods. A secondary analysis of 1190 pa-
tients not on TB treatment at recruitment also shows a
lower post-ART mortality rate among 117 patients who
started TB treatment prior to initiating ART (HR 0.37
95 % CI 0.19, 0.72 p-value 0.004).
Risk of death before starting ART appears higher
among patients with very high phosphate values (Fig. 1),
however, there is no evidence of an association in the
Table 1 Baseline characteristics of the study populationa
Variable Level n (%)
N (%) 1815 (100)
Lusaka 1111 (61.2)
Age (years), median (IQR) 35 (29–41)
Female 900 (49.6)
BMI (kg/m2), median (IQR) 16.7 (15.6–17.5)
BMI <17 kg/m2 1074 (59.2)
CD4 count (cells/μl), median (IQR) 120 (51–211)
CD4 count group > = 200 494 (27.2)
100–199 531 (29.3)
50–99 347 (19.1)
<50 443 (24.4)
Haemoglobin (g/L), median (IQR) 96 (80–111)
Haemoglobin groupb Normal 177 (9.8)
Mild anaemia 285 (15.7)
Moderate anaemia 810 (44.6)
Severe anaemia 398 (21.9)
Missing 145 (8.0)
Phosphate <0.87 mmol/L <0.87 196 (10.8)
Missing 51 (2.8)
Marital status Married/Cohabiting 858 (47.3)
Widowed 203 (11.2)
Divorced-Separated 510 (28.1)
Single 243 (13.4)
Missing 1 (<0.1)
Occupation Salaried 271 (14.9)
Self-employed 945 (52.1)
Housewife 183 (10.1)
Student 18 (1.0)
Unemployed 397 (21.9)
Missing 1 (<0.1)
Education None 343 (18.9)
Primary 1045 (57.6)
Secondary 377 (20.8)
Tertiary 49 (2.7)
Missing 1 (<0.1)
TB treatment at baseline 304 (16.9)
Oedema at baseline 66 (3.6)
Initial ART regimen (% of 1474
patients who started ART)
AZT/3TC/EFV 135 (9.2)
AZT/FTC/NVP 236 (16.0)
TDF/FTC/EFV 816 (55.4)
Table 1 Baseline characteristics of the study populationa
(Continued)
TDF/FTC/NVP 64 (4.3)
Other 54 (3.7)
Missing 169 (11.5)
aBMI body mass index, CI confidence interval, LNS lipid-based nutritional
supplement without added vitamins and minerals, LNS-VM lipid nutritional
supplement with added vitamins and minerals, AZT Zidovudine, 3TC
Lamivudine, NVP nevirapine, TDF tenofovir, EFV efavirenz; FTC emtricitabine
bHaemoglobin categories were selected based on usual nutritional cut-offs,
not as defined for specific adverse events; adequate haemoglobin was defined
as 130 g/L for men and 120 g/L for women; mild anaemia was 110 g/L to the
adequate cut-off; moderate anaemia was 80–109 g/L; severe
anaemia was < 80 g/L
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Table 2 Mortality rates by potential baseline risk factorsa
n deaths Mortality rate per 100 person-years (95 % CI)
Total population 1815 365 83.1 (75.0 to 92.1)
Study period Pre-ART 1784e 151 120.8 (103.0 to 141.7)
Post-ART 1441 195 66.1 (57.4 to 76.1)
Days Pre-ART 0–13 1784 46 73.6 (55.1 to 98.3)
14–20 1401 25 119.0 (80.4 to 176.2)
21–27 867 20 151.4 (97.6 to 234.6)
28–70 554 60 211.9 (164.5 to 272. 9)
Days Post-ART 0–13 1441 44 81.3 (60.5 to 109.2)
14–27 1380 39 75.5 (55.1 to 103.3)
28–41 1326 35 70.4 (50.5 to 98.0)
42–55 1277 32 66.9 (47.3 to 94.6)
56–69 1266 24 52.2 (35.0 to 77.9)
≥70 1184 21 46.0 (30.0 to 70.5)
Site Lusaka 1111 170 64.4 (55.4 to 74.9)
Mwanza 704 195 122.3 (106.3 to 140.8)
Sex Women 900 156 72.6 (62.0 to 84.9)
Men 915 209 100.3 (87.6 to 114.9)
Age group (years) 18–29 463 85 80.1 (64.7 to 99.1)
30–39 788 159 87.5 (74.9 to 102.2)
40–49 411 81 82.2 (66.1 to 102.1)
> = 50 153 40 108.3 (79.4 to 147.6)
Socioeconomic quintiles Highest 360 73 85.4 (67.9 to 107.5)
High 355 77 93.0 (74.3 to 116.2)
Middle 362 72 84.7 (67.2 to 106.7)
Low 374 81 93.9 (75.5 to 116.8)
Lowest 364 62 74.0 (57.7 to 94.9)
CD4 group (cells/μl) > = 200 494 59 48.1 (37.3 to 62.1)
100–199 531 82 64.5 (51.9 to 80.1)
50–99 347 88 112.0 (90.9 to 138.0)
<50 443 136 143.3 (121.1 to 169.5)
BMI group (kg/m2) 17.0–18.49 741 106 57.7 (47.7 to 69.8)
16.0–16.9 468 93 85.5 (69.8 to 104.8)
<16.0 606 166 126.9 (109.0 to 147.7)
Haemoglobin (g/L) b > = 120/130 177 15 33.2 (20.0 to 55.0)
110–119/129 285 39 53.7 (39.2 to 73.4)
80–190 810 158 83.5 (71.4 to 97.6)
<80 398 127 153.9 (129.3 to 183.1)
Oedema No 1749 335 81.5 (73.2 to 90.7)
Yes 66 30 245.5 (171.7 to 351.1)
On Tuberculosis Treatment No 1511 320 93.0 (83.3 to 103.7)
Yes 304 38 50.2 (36.5 to 69.0)
On cotrimoxazole No 319 59 77.7 (60.2 to 100.3)
Yes 1486 302 87.5 (78.2 to 98.0)
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study overall (Table 3). There were few patients with
extremely abnormal values (Table 2), so power to detect
an association is low.
One fifth of patients died from confirmed or suspected
TB. Respiratory tract infections and diarrhoea were
also common diagnoses for patients who died. Cause
of death was not confirmed for one third of patients,
the majority of whom died at home (Additional file 1:
Table S1).
Discussion
The high mortality observed around the initiation of
ART is a major concern for programme managers and
clinicians in Africa. To our knowledge, this is one of the
first studies to assess risk factors for mortality in both
the period from referral for ART and in the early post-
ART period among malnourished adults, a group com-
prising a third of new patients in some low-resource
settings [2]. Well-established risk factors we found con-
sistent with previous studies [4, 6, 9] include low BMI,
low fat-free mass, low CD4, high CRP, and male sex.
Less-frequently investigated factors associated with an
increase in mortality include oedema, low grip strength
and low MUAC. More surprising results were seen with
TB treatment and phosphate level.
Overall mortality was high in our population but, when
stratified by BMI (results not shown), was similar in the
post-ART period to that found in a large Tanzanian study
[3]. This suggests our patients were not unusual in their
characteristics or medical care compared to other mal-
nourished HIV-positive adults in Africa, and supports the
validity of the extremely high mortality rates seen in the
pre-ART period. Other studies also show higher mortality
before, compared to the first months after, starting
ART [1, 22]. When examined in more detail, the mor-
tality rate in our study increased through the pre-ART
period, highlighting the extreme vulnerability of these
patients and further supporting the theory that much
early ART mortality results from advanced disease. This
confirms the value of immediate ART initiation, as
recently recommended by WHO for all persons with
HIV worldwide [23].
Table 2 Mortality rates by potential baseline risk factorsa (Continued)
Serum phosphatec Grades 3–4 low, <0.65 mmol/L 54 16 134.0 (82.1 to 218.8)
Grades 1–2 low, 0.65–0.87 mmol/L 142 28 83.5 (57.7 to 120.9)
Normal, 0.87–1.45 mmol/L 1241 232 79.6 (70.0 to 90.5)
Above normal, >1.45 mmol/L 327 74 98.3 (78.3 to 123.5)
CRP group (mg/l) <10 358 27 28.7 (19.7 to 41.8)
10–49 450 57 50.7 (39.1 to 65.8)
50–159 491 118 109.2 (91.1 to 130.7)
≥160 463 151 155.8 (132.8 to 182.7)
Fat-free mass indexc Tertiles (kg/m2) ≥14.5 486 65 55.6 (43.6 to 70.9)
13.7 to 14.49 503 81 65.2 (52.4 to 81.0)
<13.7 471 92 81.4 (66.4 to 99.9)
Fat mass indexc Tertiles (kg/m2) ≥3.0 466 62 52.2 (40.7 to 67.0)
2.2 to 2.99 520 80 62.3 (50.0 to 77.5)
<2.2 474 96 89.8 (73.5 to 109.7)
Grip strengthc Tertiles (kg) >22.2 592 79 53.6 (43.0 to 66.8)
16.2 to 22.2 588 119 85.9 (71.8 to 102.8)
<16.2 572 155 125.7 (107.4 to 147.1)
MUACc Tertiles (cm) >22.3 603 63 41.4 (32.3 to 52.9)
20.5–22.3 633 123 82.8 (69.4 to 98.8)
<20.5 566 179 150.3 (129.8 to 174.0)
Appetitec, d Tertiles > − 0.5 229 48 86.5 (65.2 to 114.8)
−1.48 to −0.55 227 59 112.8 (87.4 to 145.6)
<−1.5 228 76 158.1 (126.3 to 197.9)
aAbbreviations: BMI body mass index, MUAC mid-upper arm circumference, CRP C-reactive protein
bNormal haemoglobin cut-offs used were 120 g/L for women and 130 g/L for men
cValues were divided into tertiles for factors without established cut-offs
dAppetite score from polychoric correlation
e31 patients excluded due to missing information on ART
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We expected receipt of TB treatment, as a proxy for
TB infection, to be associated with higher risk of mortal-
ity [24] but it was actually strongly protective. This
could suggest a substantial burden of undiagnosed TB is
present in this population. A study conducted in Zambia
and Tanzania at the same time as ours but among a
Table 3 Poisson regression models for baseline factors associated with overall mortality
Factor Level Unadjusted HR (95 % CI) b p-value Adjusted HR (95 % CI) c n = 1685c Adjusted p-value
Site Zambia 1 <0.001 1 <0.001
Tanzania 1.90 (1.55 to 2.33) 1.60 (1.27 to 2.03)
Sex Female 1 0.002 1 <0.001
Male 1.38 (1.12 to 1.70) 2.05 (1.60 to 2.64)
Age group (years) 18–29 1 0.43 1 0.79
30–39 1.09 (0.84 to 1.42) 1.01 (0.77 to 1.34)
40–49 1.03 (0.76 to 1.39) 0.94 (0.67 to 1.30)
> = 50 1.35 (0.93 to 1.97) 0.84 (0.55 to 1.28)
Socioeconomic quintiles Highest 1 0.65
High 1.09 (0.79 to 1.50)
Middle 0.99 (0.72 to 1.37)
Low 1.10 (0.80 to 1.51)
Lowest 0.87 (0.62 to 1.22)
CD4 group (cells/μl) > = 200 1 <0.001 1 <0.001
100–199 1.34 (0.96 to 1.87) 1.19 (0.84 to 1.69)
50–99 2.33 (1.67 to 3.24) 1.69 (1.19 to 2.40)
<50 2.98 (2.19 to 4.04) 2.10 (1.52 to 2.91)
BMIa Per 1 kg/m2 increase 0.76 (0.71 to 0.81) <0.001 0.85 (0.78 to 0.91) <0.001
Haemoglobin Per 10 g/L increase 0.82 (0.78 to 0.86) <0.001
Oedema No 1 <0.001 1 0.004
Yes 3.01 (2.07 to 4.38) 1.84 (1.21 to 2.78)
Baseline TBa treatment No 1 <0.001 1 <0.001
Yes 0.54 (0.39 to 0.76) 0.44 (0.31 to 0.63)
Baseline cotrimoxazole treatment No 1 0.41
Yes 1.13 (0.85 to 1.49)
CRPa (mg/l) <10 1 <0.001 1 <0.001
10–49 1.77 (1.12 to 2.80) 1.61 (1.00 to 2.58)
50–159 3.80 (2.50 to 5.78) 3.03 (1.97 to 4.66)
≥160 5.43 (3.61 to 8.18) 3.67 (2.40 to 5.62)
Fat-free mass index Per 1 kg/m2 increase 0.76 (0.66 to 0.88) <0.001 0.80 (0.67 to 0.95) 0.01
Fat mass index Per 1 kg/m2 increase 0.75 (0.64 to 0.88) 0.001 0.86 (0.70 to 1.05) 0.15
Grip strength Per 1 kg increase 0.94 (0.93 to 0.96) <0.001 0.94 (0.92 to 0.96) <0.001
MUACa Per 1 cm increase 0.78 (0.74 to 0.82) <0.001 0.87 (0.82 to 0.92) <0.001
Appetite score > − 0.5 1 0.004 1 0.65
−1.49 to−0.55 1.30 (0.89 to 1.91) 1.20 (0.81 to 1.78)
<−1.5 1.83 (1.27 to 2.62 1.08 (0.72 to 1.61)
Phosphate (mmol/l) Cubic spline 0.001 0.40
aAbbreviations: BMI body mass index, MUAC mid-upper arm circumference, CRP C-reactive protein, TB tuberculosis
bn = 1815 except haemoglobin n = 1670, CRP n = 1762, fat-free mass n = 1461, grip strength n = 1752, MUAC n = 1802, appetite n = 684 (Tanzanian patients only),
phosphate n = 1764
cMultivariable analysis adjusted for age, sex, CD4, BMI, oedema, TB treatment, CRP, grip strength, site, follow-up time in 3 week bands (association with mortality
p < 0.002 except in appetite analysis p = 0.24) and study arm. Association with fat-free mass, MUAC and appetite not adjusted for BMI. n = 1685 except fat-free
mass n = 1349, MUAC n = 1672, appetite n = 630, (Tanzanian patients only), Phosphate n = 1644
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population with median BMI of 19.3 found a similar
proportion of patients (16 %) were on TB treatment at
baseline [25]. However, previous work in Tanzania has
shown that TB explains most of the weight deficit seen
in TB/HIV co-infected patients [26] so we would expect
to see more TB in our cohort of malnourished adults
than in a better-nourished population. It is also possible
that TB treatment was effective against other pathogens,
including those causing diarrhoea [27], which might
otherwise have contributed to mortality. Patients already
on TB treatment when first assessed for ART may be
better care-seekers and therefore healthier. However the
protective effect of TB treatment on post-ART mortality
remained when only studying patients who started TB
treatment after recruitment. These findings call for
greater efforts to be made to diagnose and treat TB, es-
pecially among malnourished patients for whom algo-
rithms and investigations focused on respiratory
symptoms and signs may be less sensitive. They may also
support empiric treatment for TB, especially in under-
nourished individuals; however, prioritising TB treat-
ment for HIV positive South Africans with high
probability of TB, including BMI<18.5, did not reduce
mortality [28].
Our prior studies, which formed the foundation for
NUSTART’s design, found low pre-ART serum phosphate
Table 4 Poisson regression models for baseline factors associated with mortality during the pre- and post-ART periodsa
Pre-ART period (n = 1656) c After starting ART (n = 1334) d
Factor Level Adjusted HRb (95 % CI) p-value Adjusted HRb (95 % CI) p-value
Site Zambia 1 <0.001 1 0.28
Tanzania 2.65 (1.82 to 3.84) 1.20 (0.86 to 1.66)
Sex Female 1 <0.001 1 0.16
Male 3.44 (2.31 to 5.14) 1.29 (0.90 to 1.84)
Age group (years) 18–29 1 0.65 1 0.71
30–39 1.18 (0.77 to 1.83) 0.81 (0.55 to 1.20)
40–49 1.04 (0.62 to 1.75) 0.87 (0.56 to 1.35)
> = 50 0.83 (0.43 to 1.60) 1.00 (0.56 to 1.76)
CD4 group (cells/μl) > = 200 1 0.004 1 0.001
100–199 1.23 (0.69 to 2.19) 1.34 (0.83 to 2.14)
50–99 2.08 (1.21 to 3.59) 1.60 (0.97 to 2.64)
<50 2.25 (1.35 to 3.59) 2.33 (1.49 to 3.66)
BMIa Per 1 kg/m2 increase 0.93 (0.82 to 1.05) 0.23 0.80 (0.72 to 0.89) <0.001
Oedema No 1 0.13 1 0.03
Yes 1.57 (0.88 to 2.82) 2.03 (1.09 to 3.79)
Baseline TBa treatment No 1 <0.001 1 0.003
Yes 0.32 (0.18 to 0.58) 0.49 (0.30 to 0.79)
CRPa (mg/l) <10 1 0.001 1 <0.001
10–49 0.69 (0.32 to 1.49) 3.00 (1.49 to 6.05)
50–159 2.02 (1.13 to 3.62) 4.79 (2.43 to 9.43)
≥160 1.94 (1.09 to 3.45) 5.94 (3.02 to 11.67)
Fat-free mass index Per 1 kg/m2 increase 0.97 (0.74 to 1.26) 0.78 0.70 (0.56 to 0.89) 0.003
Grip strength Per 1 kg increase 0.90 (0.87 to 0.93) <0.001 0.98 (0.95 to 1.01) 0.12
MUACa Per 1 cm increase 0.93 (0.85 to 1.02) 0.11 0.84 (0.78 to 0.91) <0.001
Appetite score > − 0.5 1 0.34 1 0.85
−1.49 to−0.55 0.90 (0.50 to 1.61) 1.00 (0.54 to 1.82)
<−1.5 1.31 (0.76 to 2.28) 1.15 (0.65 to 2.05)
Phosphate (mmol/l) Cubic spline 0.06 0.50
aAbbreviations: ART antiretroviral therapy, BMI body mass index, MUAC mid-upper arm circumference, CRP C-reactive protein, TB tuberculosis
bMultivariable analysis adjusted for age, sex, CD4, BMI, oedema, TB treatment, CRP, grip strength, site, follow-up period and study arm. Post-ART analysis also adjusted
for weeks spent pre-ART. Association with fat-free mass, MUAC and appetite not adjusted for BMI. Post-ART analysis also adjusted for weeks spent pre-ART
cPre-ART analysis; Fat-free mass n = 1331, MUAC n = 1643, Appetite n = 623, Phosphate n = 1615
dPost-ART analysis; Fat-free mass n = 1113, MUAC n = 1323, Appetite n = 478, Phosphate n = 1304
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levels to be independently associated with early ART
mortality [5, 29]. In contrast, in our population, serum
phosphate did not show evidence of an association
with overall mortality and high phosphate appeared to
carry a greater risk in the pre-ART period. Our at-
tempt to treat patients having low electrolyte levels
with oral electrolyte supplementation may have re-
duced any impact of low phosphate on mortality.
Serum phosphate levels are known to change over time
and we are planning more detailed analysis of electro-
lytes as time-varying variables.
In this population, oedema carried a high risk of death.
Very few patients presented with oedema, so the risk es-
timate lacked precision; however, oedema can be a sign
of advanced malnutrition, so it is not a surprising find-
ing. MUAC, which is routinely used in the diagnosis
and monitoring of malnourished children but rarely for
adults, was also strongly associated with mortality. It is
inexpensive and simple to measure, even in very ill pa-
tients unable to stand, and may therefore have a role in
resource-constrained settings and for severely ill patients
where measuring BMI is not an option.
While some risk factors were significantly associated
with mortality in both the pre-and post-ART periods,
there are some interesting exceptions. Male sex was a
risk only in the pre-ART period, possibly reflecting later
care-seeking by men but an equivalently good response
to ART as in women.
Grip strength is often considered a functional indicator
of lean mass, and there is also evidence of an association
with lipodystrophy and inflammation in HIV patients
[30]. However, in this population low grip strength
carried a risk for mortality independent of BMI and
serum CRP. Grip strength of HIV positive adults starting
ART in Ethiopia was improved by a lipid-based nutri-
tional supplement [31] and it has been used as a compo-
nent of ‘frailty’ in monitoring African patients on ART
[32]. Therefore, further research is warranted into what
affects grip strength, how it interacts with body compos-
ition, fat distribution, and inflammation, and how it
performs as an adjunct to clinical care in populations at
different stages of HIV or ART treatment.
Mortality was higher in Mwanza than Lusaka even in
adjusted analyses that controlled for the slightly lower
CD4 counts in Mwanza. This could be partly explained by
the tracing of non-attendees to their home in Mwanza,
but only by phone in Lusaka, therefore identifying more
patients who died during the study. There may also have
been additional, unmeasured factors indicative of more se-
vere disease in Mwanza patients and the effect of localised
conditions such as the higher incidence of malaria in
Mwanza. Of note, once the Tanzanian patients were on
ART treatment, they did as well as those in Zambia.
Our study benefited from a large sample size, excellent
follow-up for the mortality outcome, and rich database
of interview and anthropometric measures and bio-
markers. It had several limitations as well. Due to finan-
cial constraints, we were unable to measure HIV viral
load. Data on cause of death were often missing or unre-
liable, so we could not investigate how risk factors were
associated with particular causes. Appetite could be ana-
lysed only for Mwanza patients because the appetite
score was clustered and possibly unreliable in Lusaka,
[18] so this analysis was under-powered. TB data relied
on patient self-report which could be unreliable, how-
ever, this is unlikely to explain the large effect seen,
especially in a population with high TB awareness and
understanding. We could not analyse associations of
particular ART regimens with mortality because there
was a large difference in regimens between sites and the
sites themselves differed in mortality risk.
Fig. 1 Adjusted hazard ratio* for baseline phosphate compared
to median value of 1.2 mmol/l (using cubic splines with 4 knots).
a. Hazard ratio throughout the study period. b. Hazard ratio in
the pre-ART period. *Multivariable analysis adjusted for age sex,
CD4, Hb, BMI, oedema, TB treatment, Cotrimoxazole, CRP, grip
strength, site, follow-up period and study arm. Results shown for
baseline phosphate <3mmol/l
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Conclusions
Our results extend knowledge of risk factors for mortal-
ity of HIV patients to the high risk period between refer-
ral for ART and ART initiation which in most African
clinics lasts several weeks. The extremely high mortality
that occurred during this period provides further sup-
port for minimising delays in diagnosis and treatment
initiation, especially among malnourished patients. The
strong association between TB treatment and reduced
mortality supports more commitment to diagnosis of TB
of underweight patients commencing ART.
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